Real-World Evidence Evaluation on the Lipid Profile, Therapeutic Goals, and Safety of the Fixed-Dose Combination of Rosuvastatin/Ezetimibe (Trezete®) in Dyslipidemia Patients.
Joel Rodríguez-SaldañaFrancisco Padilla-PadillaErnesto German Cardona MuñozYulia Romero-AntonioMaría Marcela Arguedas-NúñezJosé G Sander-PadillaAlberto Martínez-MuñozLaura A Lugo-SánchezIleana C Rodríguez-VázquezJorge Gonzalez-CanudasPublished in: Cardiology research and practice (2022)
Trezete® shows an important clinical impact on CVR-related target markers during the treatment of dyslipidemia patients. It is relevant to mention that a significant percentage of patients achieved therapeutic goals during the first months of treatment. Fixed-dose combination therapy has shown to be as safe as monotherapy treatment. ClinicalTrials.gov Identifier: NCT04862962.